GT Biopharma, Inc. (GTBP) stock
GTBPNasdaqPharmaceutical PreparationsFiscal year ends December 31
$2.96−0.22 (-6.92%)
Close on Nov 20, 2026Market cap $133.52MP/E –Yield –
GT Biopharma net income
Net income is the profit left for shareholders after every expense, interest and tax.
GT Biopharma's net income for the twelve months ending Jun 30, 2026 was -$4.76M. For fiscal 2025 it was -$28.35M. The highest annual figure on record is $9.77M in fiscal 2016.
Annual net income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$28.35M | – |
| FY2024 | Dec 31, 2024 | -$13.16M | – |
| FY2023 | Dec 31, 2023 | -$7.60M | – |
| FY2022 | Dec 31, 2022 | -$20.88M | – |
| FY2021 | Dec 31, 2021 | -$58.01M | – |
| FY2020 | Dec 31, 2020 | -$28.30M | – |
| FY2019 | Dec 31, 2019 | -$38.65M | – |
| FY2018 | Dec 31, 2018 | -$259.19M | – |
| FY2017 | Dec 31, 2017 | -$144.17M | -1576.0% |
| FY2016 | Dec 31, 2016 | $9.77M | – |
| FY2015 | Dec 31, 2015 | -$21.46M | – |
| FY2014 | Dec 31, 2014 | -$23.49M | – |
| FY2013 | Dec 31, 2013 | -$501.00K | – |
| FY2012 | Dec 31, 2012 | -$5.17M | – |
| FY2011 | Dec 31, 2011 | -$3.70M | – |
| FY2010 | Dec 31, 2010 | -$3.00M | – |
Quarterly net income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$4.52M | – |
| Q1 FY2026 | Mar 31, 2026 | -$2.83M | – |
| Q4 FY2025 | Dec 31, 2025 | -$5.71M | – |
| Q3 FY2025 | Sep 30, 2025 | $8.30M | – |
| Q2 FY2025 | Jun 30, 2025 | -$30.17M | – |
| Q1 FY2025 | Mar 31, 2025 | -$776.00K | – |
| Q4 FY2024 | Dec 31, 2024 | -$3.78M | – |
| Q3 FY2024 | Sep 30, 2024 | -$3.41M | – |
| Q2 FY2024 | Jun 30, 2024 | -$3.71M | – |
| Q1 FY2024 | Mar 31, 2024 | -$2.27M | – |
| Q4 FY2023 | Dec 31, 2023 | -$2.96M | – |
| Q3 FY2023 | Sep 30, 2023 | -$2.42M | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.99M | – |
| Q1 FY2023 | Mar 31, 2023 | -$227.00K | – |
| Q4 FY2022 | Dec 31, 2022 | -$5.58M | – |
| Q3 FY2022 | Sep 30, 2022 | -$6.88M | – |
| Q2 FY2022 | Jun 30, 2022 | -$2.98M | – |
| Q1 FY2022 | Mar 31, 2022 | -$5.44M | – |
| Q4 FY2021 | Dec 31, 2021 | -$18.02M | – |
| Q3 FY2021 | Sep 30, 2021 | -$5.45M | – |
| Q2 FY2021 | Jun 30, 2021 | -$4.86M | – |
| Q1 FY2021 | Mar 31, 2021 | -$29.68M | – |
| Q4 FY2020 | Dec 31, 2020 | -$6.29M | – |
| Q3 FY2020 | Sep 30, 2020 | -$2.88M | – |
| Q2 FY2020 | Jun 30, 2020 | -$17.42M | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.71M | – |
| Q4 FY2019 | Dec 31, 2019 | -$1.47M | – |
| Q3 FY2019 | Sep 30, 2019 | -$29.88M | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.79M | – |
| Q1 FY2019 | Mar 31, 2019 | -$4.51M | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.23M | – |
| Q3 FY2018 | Sep 30, 2018 | -$235.78M | – |
| Q2 FY2018 | Jun 30, 2018 | -$9.08M | – |
| Q1 FY2018 | Mar 31, 2018 | -$10.09M | – |
| Q4 FY2017 | Dec 31, 2017 | -$6.03M | – |
| Q3 FY2017 | Sep 30, 2017 | -$130.63M | – |
| Q2 FY2017 | Jun 30, 2017 | -$2.46M | – |
| Q1 FY2017 | Mar 31, 2017 | -$5.06M | – |
| Q4 FY2016 | Dec 31, 2016 | -$2.83M | – |
| Q3 FY2016 | Sep 30, 2016 | -$3.63M | – |
See a number that looks wrong?